Evidence map›Paper›PMID 41732118›Full record

ArticleDrug testing and analysis2026

Bromazolam Tablet Quantification and Analysis of Post-Mortem Cases From the National Programme on Substance Use Mortality (NPSUM).

Matthew Gardner, Molly F Millea, Sam Craft, Rachael Andrews, Jennifer Scott, Stephen M Husbands, Christopher R Pudney, Oliver B Sutcliffe, Caroline S Copeland, Peter Sunderland

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew GardnerDepartment of Life Sciences, University of Bath, Bath, UK.ORCID https://orcid.org/0009-0004-5206-1259
Molly F MilleaMANchester DRug Analysis & Knowledge Exchange (MANDRAKE), Department of Natural Sciences, Manchester Metropolitan University, Manchester, UK.ORCID https://orcid.org/0009-0005-2543-3202
Sam CraftDepartment of Psychology, University of Bath, Bath, UK.ORCID https://orcid.org/0000-0002-5663-2731
Rachael AndrewsDepartment of Life Sciences, University of Bath, Bath, UK.ORCID https://orcid.org/0000-0002-7836-036X
Jennifer ScottCentre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0002-4920-0914
Stephen M HusbandsDepartment of Life Sciences, University of Bath, Bath, UK.ORCID https://orcid.org/0000-0002-9928-6322
Christopher R PudneyDepartment of Life Sciences, University of Bath, Bath, UK.ORCID https://orcid.org/0000-0001-6211-0086
Oliver B SutcliffeMANchester DRug Analysis & Knowledge Exchange (MANDRAKE), Department of Natural Sciences, Manchester Metropolitan University, Manchester, UK.ORCID https://orcid.org/0000-0003-3781-7754
Caroline S CopelandCentre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, London, UK.ORCID https://orcid.org/0000-0002-4462-1402
Peter SunderlandDepartment of Life Sciences, University of Bath, Bath, UK.ORCID https://orcid.org/0009-0001-5020-8251

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bromazolam is a new psychoactive substance (NPS) benzodiazepine commonly identified by drug checking services and in post-mortem toxicological analyses in the United Kingdom, Europe, and North America. At the time of writing, there are no studies that present quantitative analyses of bromazolam in street tablets. Here we describe the first quantitative analysis of bromazolam tablets, from samples submitted by UK drug checking services and police forces between 2022 and 2025. Using validated GC-EI-MS and

Indexed as

BenzodiazepinesIllicit DrugsSubstance-Related DisordersAutopsyGas Chromatography-Mass SpectrometryHumansMagnetic Resonance SpectroscopySubstance Abuse DetectionTabletsUnited KingdomBenzodiazepinesIllicit DrugsTablets

Identifiers

PMID41732118
PMCPMC13040413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.